SOPHiA GENETICS SA (SOPH) reported Q3 EPS of ($0.36), in-line with the analyst estimate of ($0.36). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $11.45 million.
2022 Outlook:
We are reaffirming our previously provided guidance of constant currency revenue growth range of 30% to 35% for full-year 2022. Based on our latest view of the impact of movements in the foreign exchange rates between our key transactional currencies, including the euro, the Swiss franc, the British pound, and the Turkish lira, and the U.S. dollar, we now expect full-year 2022 reported revenue to be at the low-end of our previously provided range of $47.0 million to $49.5 million.